SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 13:50:37 2024-05-31 EDT | ||
| 2.97 EUR | -1.33% |
|
| 1 month | +11.24% | ||
| 3 months | +40.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 2.97 | -1.33% |
| 24-05-30 | 3.01 | -0.66% |
| 24-05-29 | 3.03 | +1.00% |
| 24-05-28 | 3 | +2.74% |
| 24-05-27 | 2.92 | +0.34% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 01:50 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU3W1C |
| ISIN | DE000VU3W1C3 |
| Date issued | 2023-02-23 |
| Strike | 73.18 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.06 € |
|---|---|
| Lowest since issue | 0.3 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
- Stock Market
- Certificates
- Certificat
